Connect with us

Hi, what are you looking for?

Estrogen Among Women With Prior Hysterectomy Reduces Breast Cancer Mortality

New Long-Term Follow-Up Study Published Today in JAMA (Journal of the American Medical Association) Shows Noteworthy Results

LOS ANGELES – July 29, 2020 – (

The Lundquist Institute announced today a new study published in JAMA (Journal of the American Medical Association) which examined the link between hormonal therapy, particularly estrogen and progestin, and the incidence of breast cancer mortality. The team found that the use of estrogen alone among women who had a prior hysterectomy resulted in a lower rate of breast cancer incidence and mortality.

“The statistically significant 40 percent reduction in deaths with estrogen alone from breast cancer is remarkable,” said Corresponding Author of the study Rowan Chlebowski, MD, PhD, Lundquist Institute Investigator, Chief of the Division of Medical Oncology and Hematology at Harbor-UCLA Medical Center and Professor of Medicine at the David Geffen School of Medicine at UCLA. “In contrast, the commonly recommended chemo-prevention agents Tamoxifen and aromatese inhibitors have not been shown to reduce deaths in breast cancer.”

The goal of the study was to assess the association of prior randomized use of estrogen plus progestin or prior randomized use of estrogen alone with breast cancer incidence and mortality in the Women’s Health Initiative clinical trials.

“This new analysis confirms a noteworthy increase in breast cancer risk with the estrogen plus progestin regimen studied and a noteworthy reduction in breast cancer risk with the estrogen-alone regimen studied, over a 20-year intervention and follow-up period. These are strong randomized, controlled trial intervention influences among postmenopausal U.S. women that cannot be attributed to chance,” explained Ross Prentice, PhD, co-author and Professor, Cancer Prevention Program Clinical Research Division, Fred Hutchinson Cancer Research Center.

Max Benavidez, PhD

Media can receive a copy by emailing

This link will provide free access to the full-text article.

About the Lundquist Institute: Research with Reach

The Lundquist Institute is an engine of innovation with a global reach and a 68-year reputation of improving and saving lives. With its new medical research building, its state-of-the-art incubator, “BioLabs at The Lundquist,” existing laboratory and support infrastructure, and a 15-acre tech park in the planning stages, the Lundquist Institute serves as a hub for the Los Angeles area’s burgeoning biotech scene. The research institute has over 100 principal investigators (PhDs, MDs, and MD/PhDs) working on more than 600 research studies, including therapies for numerous, and often fatal orphan diseases.

Press Release Service

Original Source:

Estrogen Among Women With Prior Hysterectomy Reduces Breast Cancer Mortality

Written By

You may also like:

Tech & Science

Don’t be too surprised to see betting agencies getting involved in questions like this: “Would you like to make billions on new tech?” is...


China manufactures around 70 percent of the world's sex toys, most of it the "hardware" on display at the fair.

Tech & Science

Aerial view of a soybean plantation in the municipality of Montividiu, Goias State, Brazil, taken on January 22, 2024 - Copyright AFP/File Sergio LimaJoshua...


In terms of demographics, those aged 30-39 were targeted the most by fraud and cybercrimes.